← Leaderboards
Florian S Eichler
Massachusetts General Hospital
$5,053,791
Attributed
$5,053,791
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,437,102 · 6
FDA$1,575,868 · 1
By mechanism
U54$10,968,542 · 2
R01$4,047,033 · 3
K08$983,547 · 1
P41$13,848 · 1
Top collaborators
- S. Ali Fatemi12 shared
- Adeline Lucie Vanderver12 shared
- Laura Ann Adang1 shared
- Robert W Grundmeier1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Susan A Slaugenhaupt$22,094,242
- Martin L Yarmush$31,545,312
- Bakhos A. Tannous$11,831,527
- Xandra Owens Breakefield$30,735,276
- Alexander R McCampbell$133,668
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectFutureNatural HistoryBrainPhenotypeMyelinProspectiveNervous System StructureWhite MatterLeukodystrophyBiochemicalResearch PersonnelDisease ProgressionProgramsBiological MarkersMeasurementClinical Trials NetworkCollaborationsAdrenomyeloneuropathyTrainingPerformanceMutationLipidsInvestigation
Grant awards (33)
Global Leukodystrophy Initiative Clinical Trials Network (GLIA- CTN)$1,753,747
U54 · FY2025 · NS
Project 4: an observational study in parallel to a gene therapy trial in Canavan$9,363
U54 · FY2025 · NS · contact PI
Global Leukodystrophy Initiative Clinical Trials Network Gap Year Administrative Supplement$1,009,720
U54 · FY2024 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,377,421
U54 · FY2023 · NS
ALD Healthy Planet Project$511,971
U54 · FY2023 · NS
Myelin Disorders Biorepository Project (MDBP) at the Biospecimen Exchange for Neurological Disorders (BioSEND)$143,448
U54 · FY2023 · NS
Validation of the GMFC-MLD$67,640
U54 · FY2023 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,397,307
U54 · FY2022 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$137,700
U54 · FY2022 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,405,684
U54 · FY2021 · NS
Utility of advanced MRI and wearable technology to identify sensory motor outcome measures in leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL)$156,700
U54 · FY2021 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,414,956
U54 · FY2020 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,582,885
U54 · FY2019 · NS
Phase 2 Study of L-Serine in HSN Type 1$397,948
R01 · FY2016 · FD · contact PI
Safety, Tolerability and Biological Activity of L-serine in HSAN1.$102,646
R01 · FY2016 · NS · contact PI
The Role of Desoxysphingoid Bases in HSAN1$411,974
R01 · FY2015 · NS · contact PI
Phase 2 Study of L-Serine in HSN Type 1$392,750
R01 · FY2015 · FD · contact PI
Safety, Tolerability and Biological Activity of L-serine in HSAN1.$102,646
R01 · FY2015 · NS · contact PI
The Role of Desoxysphingoid Bases in HSAN1$407,854
R01 · FY2014 · NS · contact PI
Phase 2 Study of L-Serine in HSN Type 1$391,817
R01 · FY2014 · FD · contact PI
Safety, Tolerability and Biological Activity of L-serine in HSAN1.$102,646
R01 · FY2014 · NS · contact PI
The Role of Desoxysphingoid Bases in HSAN1$397,555
R01 · FY2013 · NS · contact PI
Safety, Tolerability and Biological Activity of L-serine in HSAN1.$102,646
R01 · FY2013 · NS · contact PI
The Role of Desoxysphingoid Bases in HSAN1$411,974
R01 · FY2012 · NS · contact PI
Phase 2 Study of L-Serine in HSN Type 1$393,353
R01 · FY2012 · FD · contact PI
The Role of Desoxysphingoid Bases in HSAN1$431,224
R01 · FY2011 · NS · contact PI
1-DEOXYDIHYDROCERAMIDES IN HEREDITARY SENSORY & AUTONOMIC NEUROPATHY TYPE I$13,848
P41 · FY2011 · RR · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$175,635
K08 · FY2010 · NS · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$175,635
K08 · FY2009 · NS · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$105,372
K08 · FY2009 · NS · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$175,635
K08 · FY2008 · NS · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$175,635
K08 · FY2007 · NS · contact PI
Imaging the Pathophysiology of AMN in Mice and Humans$175,635
K08 · FY2006 · NS · contact PI